Form 4: Kymera Therapeutics CEO Nello Mainolfi Reports Exercise and Sale of Shares Under Pre-Arranged 10b5-1 Plan

Kymera Therapeutics, Inc. CEO Nello Mainolfi reported the exercise of stock options and subsequent sale of 30,000 shares of common stock on June 3, 2025, pursuant to a pre-arranged 10b5-1 trading plan.

Summary

• Nello Mainolfi, Chief Executive Officer and Director of Kymera Therapeutics, Inc. (KYMR), reported transactions on June 3, 2025.
• He exercised stock options to acquire 30,000 shares of common stock at an exercise price of $2.08 per share.
• Concurrently, he sold 30,000 shares of common stock at a price of $49.00 per share.
• Both the option exercise and the sale were conducted under a Rule 10b5-1 trading plan that was established on September 6, 2024.
• Additionally, 523 shares were acquired under the company's employee stock purchase plan on June 2, 2025.
• Following these reported transactions, Mr. Mainolfi beneficially owns 660,482 shares of common stock directly and 465,559 fully vested and exercisable stock options.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While an insider sale can sometimes be viewed negatively, the fact that it was pre-planned under a 10b5-1 plan mitigates concerns. The significant profit margin on the exercised options is a positive for the insider, reflecting a strong stock performance relative to the option strike price.

Positives

• The transactions were executed under a pre-arranged Rule 10b5-1 trading plan, indicating a systematic and planned approach to share disposition rather than a reactive sale.
• The sale price of $49.00 per share is significantly higher than the exercise price of $2.08, indicating a substantial profit for the insider on the exercised options.

Negatives

• The sale of 30,000 shares by a key executive, even if pre-planned, could be perceived negatively by some investors as it reduces the insider's direct equity stake.

Future Outlook

This Form 4 filing reports past transactions and does not contain forward-looking statements or guidance regarding the company's future performance or outlook.

Management Comments

• The transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 6, 2024 adopted by the reporting person.

Industry Context

Insider transactions, particularly sales, are common in the biotechnology and pharmaceutical industries, where executive compensation often includes significant equity components. The use of a Rule 10b5-1 plan is a standard practice for insiders to sell shares systematically and avoid accusations of trading on material non-public information.

Stakeholder Impact

• Shareholders: The sale by the CEO could be interpreted differently by shareholders; some may view it as a routine diversification, while others might see it as a lack of confidence, though the 10b5-1 plan mitigates the latter. The significant profit on the options exercise indicates value creation for the insider, which generally aligns with shareholder interests.
• Employees: The acquisition of shares through an employee stock purchase plan (ESPP) indicates ongoing employee participation in the company's equity, which is generally positive for employee alignment.

Next Steps

• This document does not outline any specific future actions, events, or milestones for the company, as it is a report of past insider trading activity.

Key Dates

Keywords

Kymera Therapeutics, KYMR, Form 4, Insider Trading, Stock Option Exercise, Stock Sale, Nello Mainolfi, 10b5-1 Plan, Beneficial Ownership, CEO